MOA Life Plus Co. Ltd. Logo

MOA Life Plus Co. Ltd.

Develops biopharmaceuticals and consumer healthcare products using γ-PGA technology.

142760 | KO

Overview

Corporate Details

ISIN(s):
KR7142760008
LEI:
Country:
South Korea
Address:
경기도 용인시 수지구 신수로 767 7층 (동천동, 분당수지유타워 지식산업센터), 용인시

Description

MOA Life Plus Co. Ltd. is a biopharmaceutical company that researches and develops innovative medicines and consumer healthcare products. The company's pharmaceutical division focuses on a pipeline of biopharmaceuticals, including immunotherapies, cancer treatments, and vaccines for infectious diseases. A core platform technology utilizes Gamma-Polyglutamic Acid (γ-PGA), a natural amino acid polymer derived from fermented foods, to enhance immune responses and serve as a vaccine adjuvant. The consumer business division provides tailored healthcare solutions for immunity enhancement, skin rejuvenation, and pet care. It also manufactures and supplies γ-PGA-based raw materials for the cosmetics industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2019-03-25 00:00
정기주주총회결과
Korean 28.0 KB
2019-03-22 00:00
증권발행결과(자율공시)(제5회차 CB)
Korean 6.0 KB
2019-03-20 00:00
장래사업ㆍ경영계획(공정공시)
Korean 14.3 KB
2019-03-15 00:00
감사보고서제출
Korean 26.8 KB
2019-03-15 00:00
주요사항보고서(전환사채권발행결정)
Korean 37.8 KB
2019-03-05 00:00
주주총회소집공고
Korean 172.5 KB
2019-03-05 00:00
의결권대리행사권유참고서류
Korean 158.0 KB
2019-02-28 00:00
주식매수선택권부여에관한신고
Korean 20.2 KB
2019-02-28 00:00
주주총회소집결의
Korean 14.1 KB
2019-02-27 00:00
주요사항보고서(전환사채권발행결정)
Korean 37.5 KB
2019-02-22 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 12.7 KB
2019-01-21 00:00
주요사항보고서(전환사채권발행결정)
Korean 31.5 KB
2018-12-21 00:00
전환가액의조정(제3회차)
Korean 12.4 KB
2018-12-21 00:00
주식등의대량보유상황보고서(약식)
Korean 52.3 KB
2018-12-17 00:00
신주인수권행사가액의조정(제2회차, 제3회차)
Korean 16.8 KB

Automate Your Workflow. Get a real-time feed of all MOA Life Plus Co. Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MOA Life Plus Co. Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MOA Life Plus Co. Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.